The ranitidine lawsuit update as of 2026 is grim for plaintiffs and mostly settled for the largest defendants. The federal multidistrict litigation has been dead since December 2022 with an appeal still unresolved at the Eleventh Circuit. Delaware, once the biggest state venue, dismissed more than 80,000 cases in April 2026. GSK has agreed to pay up to $2.2 billion to close roughly 80,000 state-court claims, Sanofi settled about 4,000 cases for over $100 million, and Pfizer has reportedly settled most of its cases. Boehringer Ingelheim is the outlier, heading toward bellwether trials in Connecticut starting March 14, 2028.
The Federal MDL Is Effectively Over
Thousands of Zantac cases were consolidated as MDL No. 2924 in the Southern District of Florida before Judge Robin Rosenberg.1United States District Court Southern District of Florida. Multi-District Litigation On December 6, 2022, she granted the defendants’ motions to exclude every one of the plaintiffs’ expert witnesses. Her ruling found that no scientist outside the litigation had concluded ranitidine causes cancer, and that the plaintiffs’ hired experts relied on unreliable methodologies, lacked documentation for how experiments were conducted, and made analytical leaps without statistically significant data. With no admissible expert testimony to prove causation, the federal cases were dismissed.
Plaintiffs appealed to the U.S. Court of Appeals for the Eleventh Circuit. As of early 2026, that appeal remains pending with no opinion and no indication of when one will come. A reversal would revive federal claims for tens of thousands of plaintiffs, but the trial court’s ruling was thorough and the appeal has sat without action for a long time.
Delaware Dismissed More Than 80,000 Cases in April 2026
When the federal MDL collapsed, plaintiffs pivoted to state courts, where evidentiary rules differ. Delaware became the largest single venue after its Superior Court denied defense motions to exclude plaintiffs’ experts and let the cases move toward trial.2Justia. In Re Zantac (Ranitidine) Litigation
The Delaware Supreme Court reversed that decision in early 2025, holding that the Superior Court had improperly presumed expert testimony was admissible. Plaintiffs, the high court ruled, carried the burden of showing by a preponderance of the evidence that their experts’ opinions rested on sufficient facts, dependable methods, and reliable application to the case, and they had not carried it.3Supreme Court of the State of Delaware. In Re Zantac (Ranitidine) Litigation The case went back to the Superior Court.
In April 2026, Delaware Superior Court Judge Francis Jones dismissed more than 80,000 remaining Zantac cases. He concluded that plaintiffs could not produce legitimate evidence connecting ranitidine to cancer and were not entitled to amend their claims. The Delaware pathway is closed.
Where Cases Are Still Active
Litigation continues in several state venues:
- California, where cases are organized under Judicial Council Coordination Proceeding No. 5150 (“Ranitidine Product Cases”).
- Illinois, another major venue with ongoing proceedings.
- Connecticut, where bellwether trials against Boehringer Ingelheim are scheduled to begin March 14, 2028, starting with colorectal cancer cases, followed by stomach cancer cases in September 2028 and prostate cancer cases in early 2029.
- Pennsylvania, where Philadelphia mass tort cases remain active, though disputes over judicial recusal have slowed proceedings.
The Connecticut trials are the most important upcoming event in the entire litigation. Plaintiff wins there could drive new settlements. Defense wins would drain leverage from remaining claims quickly. Boehringer Ingelheim already prevailed in two cases tried in early 2025.
Settlements Already in Place
GSK: Up to $2.2 Billion
GSK reached the largest settlement, resolving roughly 93% of U.S. state-court Zantac product liability cases — approximately 80,000 claims — for up to $2.2 billion. Separately, GSK agreed to pay $70 million to resolve a qui tam complaint filed by Valisure.4GSK. Statement – Zantac (Ranitidine) Litigation – Settlement Agreements Reached The settlement was expected to be fully implemented by mid-2025, so most eligible claimants should already have registered or received instructions from their attorneys.
Sanofi: Over $100 Million
Sanofi agreed to pay more than $100 million to settle approximately 4,000 state-court lawsuits, averaging roughly $25,000 per claim, though individual payouts vary based on cancer type, stage, and other factors. Sanofi, like the other defendants, denied liability.
Pfizer and Boehringer Ingelheim
Pfizer has reportedly agreed to settle most state-court cases against it. Boehringer Ingelheim has taken the opposite approach, winning two early trials in 2025 and preparing to defend the Connecticut bellwethers starting in 2028.
How Settlement Amounts Are Calculated
Large pharmaceutical settlements use a matrix that assigns compensation levels based on individual factors. The biggest variables are the type and stage of cancer: a Stage IV terminal diagnosis receives substantially more than a Stage I cancer that was treated and resolved. Surgical history matters, as does the duration of ranitidine use, dosage, the claimant’s age at diagnosis, and the strength of the medical evidence tying the drug to the illness. The matrices themselves are usually confidential. Your attorney should be able to tell you where your claim falls and give a realistic range before you agree to participate.
Filing Deadlines If You Haven’t Filed Yet
Every state imposes a statute of limitations on product liability claims, typically two to four years, though the exact period varies. Most states apply the discovery rule, meaning the clock starts when you were diagnosed with cancer or reasonably should have discovered the link between the drug and your illness, not when you first took the medication. Defendants may argue you should have known sooner given the publicity around the April 2020 recall, so documenting when you actually learned about the connection matters.
Settlement participation windows are separate from statutes of limitations and often shorter. The GSK settlement was expected to be fully implemented by mid-2025. If you think you have a qualifying claim and haven’t spoken with an attorney, both litigation deadlines and settlement registration deadlines are working against you.
Documentation You Will Need
Whether you are joining a settlement or filing a new lawsuit, you need proof of a qualifying diagnosis and proof of ranitidine use.
The cancers most commonly associated with ranitidine claims include bladder, stomach, liver, pancreatic, and breast cancer, though other malignancies with established NDMA associations may qualify depending on the specific settlement. Medical records should include pathology reports confirming the diagnosis, physician notes documenting date and stage, and treatment records showing surgical history.
Proof of drug use is where many claims fail. Pharmacy records, prescription histories, and purchase receipts all help. Over-the-counter purchases are harder to document because pharmacies may not keep records of non-prescription sales. Credit card or bank statements showing pharmacy purchases during the relevant period can serve as supporting evidence. Claim forms typically require specific duration and dosage information, so vague recollections are not enough, and discrepancies between what you report and what your records show can result in denial. Start pulling records early. Medical facilities may charge per-page fees, and large files can take weeks.
What Comes Out of Your Payment Before You See It
The gross settlement is not what you take home. Attorney contingency fees in personal injury cases typically run 33% to 40%, and litigation costs — filing fees, expert witness fees, medical record retrieval, and depositions — come out on top of that. Those terms should be in your retainer agreement. Ask your attorney for an itemized projection before the settlement finalizes.
Medicare and Medicaid Liens
If Medicare paid for cancer treatment that is later covered by your settlement, federal law requires reimbursement out of the settlement proceeds.5Office of the Law Revision Counsel. 42 USC 1395y – Exclusions from Coverage and Medicare as Secondary Payer The Benefits Coordination and Recovery Center issues a Conditional Payment Notification listing what Medicare considers related to your claim, and you have 30 calendar days to respond and dispute any charges you believe are unrelated.6Centers for Medicare and Medicaid Services. Medicare’s Recovery Process Your attorney can submit documentation of legal fees so that Medicare’s recovery is reduced proportionally for procurement costs. Ignoring the lien is not an option; interest starts accruing 60 days after notice, and the obligation follows you regardless of whether you’ve spent the money. Medicaid has similar recovery rights at the state level.
Taxes
Federal tax law generally excludes damages received on account of personal physical injuries or physical sickness from gross income, so the compensatory portion of a Zantac settlement covering the cancer itself, related pain and suffering, medical expenses, and lost wages is typically not taxable.7Office of the Law Revision Counsel. 26 USC 104 – Compensation for Injuries or Sickness Punitive damages are taxable regardless. So is interest on the settlement. And if you previously deducted medical expenses on a tax return and the settlement then reimburses those expenses, the reimbursed amount becomes taxable income under the tax benefit rule. A tax professional who handles personal injury settlements is worth a call.
Wrongful Death Claims
If a family member died from cancer potentially linked to ranitidine, a surviving spouse, child, or estate representative can generally file a wrongful death or survival action in most states. The evidentiary requirements are the same — diagnosis, drug use, causation — with the added step of establishing legal authority to act on behalf of the deceased. An executor or personal representative named in the decedent’s will, or appointed by a probate court, typically signs settlement releases and handles distribution. If no estate has been opened, opening one can add months to the process, so families should start the probate work early.
What to Watch Next
Two things will move the needle. The first is the Eleventh Circuit’s ruling on the federal MDL appeal, still pending with no timetable. A reversal would reopen federal claims for tens of thousands of plaintiffs, though the odds look long. The second is Connecticut. The bellwether trials against Boehringer Ingelheim starting March 14, 2028 will test whether plaintiffs can prove causation to a jury after two defense wins in early 2025. Those verdicts will shape whether Boehringer settles or keeps fighting, and they will influence what’s left of the litigation everywhere else.